Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Banking On China's Emerging Neuropathic Pain Market For Lyrica

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Pfizer Inc. has high expectations for its neuropathic pain blockbuster Lyrica (pregabalin) in China with its initial indication for post-herpetic neuralgia (PHN), but patient education will be key as neuropathic pain is not widely known within China

You may also be interested in...

Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)

[Editor's note: This is part two of a two-part story; part one appeared in PharmAsia News, March 4, 2011.]

Pfizer, Roche, AstraZeneca: Emerging Markets Earnings Roundup (Part 3)

Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.

AstraZeneca, Pfizer, GlaxoSmithKline: Emerging Markets Earnings Roundup (Part 2 of 2)

Restructuring and diversification was the theme of third quarter earnings calls, as both American and European Big Pharma companies continued to shift resources into emerging markets. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights. Part one covered analysis of Eli Lilly, J&J and Novartis.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts